The Independent Association of Young Entrepreneurs of Catalonia (AIJEC) has awarded the Award for the Best Business Initiative of its 25th edition to Peptomyc. Peptomyc is a spin-off of
News & Events
Our next events
Our IP Blog
ABG IP again in top position in IAM Patents 1000 – The World’s Leading Patent Practitioners 2018 for the seventh consecutive year
ABG IP is pleased to announce that it has again been ranked as “highly recommended Intellectual Property firm in Spain” according to the magazine Intellectual Asset Management (IAM). ABG
On June 7, 2018, ABG IP organized the fourth edition of the “IP Perspectives” seminar, which took place at the NH Paseo de la Habana Hotel in Madrid.
Last 28.05.2018 the European Commission published a Proposal of Regulation to modify Regulation No. 469/2009 on Supplementary Protection Certificates for medicaments. Basically, the proposal contemplates that, for SPCs granted
Spherium Biomed announced on May 17, 2018 that it has obtained positive results with its new drug Mucomel® in a phase I/IIa clinical trial for the
This phase IIa clinical study in paediatric and adult patients with mild to moderate atopic dermatitis is designed as a proof-of-concept, multi-centre, randomised, double-blind, vehicle-controlled
Spherium Biomed has recently signed a licensing agreement with Simini Technologies from Ontario (Canada) to develop veterinarian applications based on the Spherium’s proprietary topical cyclosporine (SP14019).
We are pleased to announce that Jose Miguel Lissén has joined ABG IP as partner in charge of our new Legal & Litigation department. José Miguel Lissén is a lawyer and
Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), receives approval